On Oct 24, major Wall Street analysts update their ratings for $Regeneron Pharmaceuticals (REGN.US)$, with price targets ranging from $1,080 to $1,242.
J.P. Morgan analyst Chris Schott maintains with a buy rating, and adjusts the target price from $1,200 to $1,150.
Barclays analyst Carter Gould maintains with a buy rating, and adjusts the target price from $1,220 to $1,080.
Evercore analyst Cory Kasimov maintains with a buy rating, and adjusts the target price from $1,250 to $1,175.
TD Cowen analyst Tyler Van Buren maintains with a buy rating, and maintains the target price at $1,230.
Piper Sandler analyst Christopher Raymond maintains with a buy rating, and maintains the target price at $1,242.
Furthermore, according to the comprehensive report, the opinions of $Regeneron Pharmaceuticals (REGN.US)$'s main analysts recently are as follows:
The firm has recalibrated its expectations for Eylea based on the introduction of the Pavblu generic and slightly reduced the projections for Dupixent in the latter half of 2024. Despite this, there's an optimism that the stock might have cleared previous overhangs, presenting a more favorable outlook leading up to imminent catalysts.
Regeneron's inability to obtain a stay against the Eylea biosimilar from Amgen suggests that a launch by Amgen may be forthcoming. Nonetheless, the current weakness in the stock is viewed as a buying opportunity.
Here are the latest investment ratings and price targets for $Regeneron Pharmaceuticals (REGN.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
